Comparative Assessment of Clinically Utilized CD20-directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK cell, Monocyte and Macrophage Properties

CD20 is a widely validated, B cell specific target for therapy in B cell malignancies. Rituximab is an anti-CD20 antibody that when combined with chemotherapy prolongs survival of CLL patients. Ofatumumab and GA101 (obinutuzumab) are CD20-directed antibodies now being developed as alternative agents...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Rafiq, Sarwish, Butchar, Jonathon P., Cheney, Carolyn, Mo, Xiaokui, Trotta, Rossana, Caligiuri, Michael, Jarjoura, David, Tridandapani, Susheela, Muthusamy, Natarajan, Byrd, John C.
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3631574/
https://ncbi.nlm.nih.gov/pubmed/23418626
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1202588
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars